Hansoh Pharmaceutical's 2023 Profit Up 27%

Hansoh Pharmaceutical Group (HKG:3692) recorded a 27% rise in attributable profit for 2023 to 3.28 billion yuan from 2.58 billion yuan in 2022, according to the company's annual report. Earnings per s

MT NewswiresApr 30 18:17

Hanson Pharmaceuticals (03692): Tan Sihui has been appointed as Joint Company Secretary

Hanson Pharmaceuticals (03692) announced that Li Xinying has resigned as the company's joint company secretary and will no longer serve as the Hong Kong Joint Stock Company...

Zhitong FinanceApr 29 22:30

Hanson Pharmaceuticals (03692) will pay a final dividend of HK$0.1422 per share on July 17

Hanson Pharmaceuticals (03692) announced that the company will pay a final dividend of 0 per share on July 17, 2024...

Zhitong FinanceApr 29 22:20

翰森製藥：2023年報

Futu NewsApr 29 21:43 · Announcements

Featured announcements | CNOOC's net profit for the first quarter was nearly 40 billion yuan; China Aluminum's net profit for the first quarter increased 23.01% year-on-year

ZTE's net profit for the first quarter increased by 3.74% year on year; Times Electric's net profit for the first quarter increased by 30.44% year on year.

cls.cnApr 26 08:17

Hanson Pharmaceuticals (03692.HK) subsidiary signs licensing agreement with Quanxin Biotech

Hanson Pharmaceuticals (03692.HK) announced that on April 24, 2024, Hanson (Shanghai) Health Technology Co., Ltd. (licensee), a wholly-owned subsidiary of the company, signed a licensing agreement with Jiangsu Quanxin Biomedical Co., Ltd. (Quanxin Biotech).

Zhitong FinanceApr 25 16:44